Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Q3 2025 value amounting to $29.3 million.

  • Amphastar Pharmaceuticals' Other Non-Current Liabilities rose 825.54% to $29.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 825.54%. This contributed to the annual value of $20.9 million for FY2024, which is 780.44% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Other Non-Current Liabilities of $29.3 million as of Q3 2025, which was up 825.54% from $27.8 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Other Non-Current Liabilities peaked at $29.3 million during Q3 2025, and registered a low of $13.4 million during Q1 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Other Non-Current Liabilities averaged around $18.7 million, with its median value being $15.7 million (2023).
  • The largest annual percentage gain for Amphastar Pharmaceuticals' Other Non-Current Liabilities in the last 5 years was 7222.12% (2024), contrasted with its biggest fall of 780.44% (2024).
  • Amphastar Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $15.7 million in 2021, then fell by 6.95% to $14.6 million in 2022, then skyrocketed by 55.98% to $22.7 million in 2023, then decreased by 7.8% to $20.9 million in 2024, then soared by 39.74% to $29.3 million in 2025.
  • Its last three reported values are $29.3 million in Q3 2025, $27.8 million for Q2 2025, and $24.4 million during Q1 2025.